A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of SU011248 in the Treatment of Patients With Imatinib Mesylate (Gleevec, Glivec)-Resistant or Intolerant Malignant Gastrointestinal Stromal Tumor.

Trial Profile

A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of SU011248 in the Treatment of Patients With Imatinib Mesylate (Gleevec, Glivec)-Resistant or Intolerant Malignant Gastrointestinal Stromal Tumor.

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Jun 2012

At a glance

  • Drugs Sunitinib (Primary)
  • Indications Gastrointestinal stromal tumours
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 29 Sep 2009 Actual end date changed from 10 Oct 2006 to 1 May 2008 as reported by ClinicalTrials.gov (NCT00075218).
    • 29 Sep 2009 Actual end date changed from 10 Oct 2006 to 1 May 2008 as reported by ClinicalTrials.gov (NCT00075218).
    • 25 Jun 2008 Results reported at WCGC 2008
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top